C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505218-68-00

Acronym

C4531002

Enrollment

Registered

2024-08-09

Start date

2025-06-12

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate-Severe Atopic Dermatitis

Brief summary

"EASI75 (≥75% improvement from baseline) at Week 16"

Detailed description

"vIGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points", "EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16", "Percent change from baseline in EASI total score at scheduled time points", "Incidence of treatment emergent AEs, clinically significant changes in vital signs, electrocardiogram (ECG), and laboratory tests"

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
"EASI75 (≥75% improvement from baseline) at Week 16"	—

Secondary

Measure	Time frame
"vIGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points", "EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16", "Percent change from baseline in EASI total score at scheduled time points", "Incidence of treatment emergent AEs, clinically significant changes in vital signs, electrocardiogram (ECG), and laboratory tests"	—

Measure

Time frame

—

Countries

Germany, Poland

Outcome results